Okyo Pharma released new data from its phase 2 trial of OK-101, a lipid conjugated chemerin peptide agonist, which showed a 68% improvement in both conjunctival staining and ocular pain among patients with dry eye disease.
“The data from this first in-human trial of OK-101 in patients with DED have established a clear road map for future clinical development in this indication,” Gary S. Jacob, PhD, CEO of Okyo Pharma, said in a company press release.
The randomized, double-masked, placebo-controlled trial assessed the safety and efficacy of OK-101 ophthalmic solution through 85 days